Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$0.22 - $0.5 $2,821 - $6,412
-12,824 Reduced 8.46%
138,783 $41,000
Q1 2023

May 15, 2023

BUY
$0.36 - $0.63 $6,406 - $11,212
17,797 Added 13.3%
151,607 $56,000
Q4 2022

Feb 13, 2023

SELL
$0.41 - $1.1 $205 - $550
-500 Reduced 0.37%
133,810 $64,000
Q3 2022

Nov 14, 2022

SELL
$0.57 - $1.77 $9,614 - $29,856
-16,868 Reduced 11.16%
134,310 $116,000
Q2 2022

Aug 12, 2022

SELL
$0.85 - $1.41 $414,879 - $688,211
-488,093 Reduced 76.35%
151,178 $141,000
Q1 2022

May 13, 2022

SELL
$1.16 - $2.5 $34,864 - $75,140
-30,056 Reduced 4.49%
639,271 $844,000
Q4 2021

Feb 08, 2022

SELL
$2.46 - $8.74 $8,983 - $31,918
-3,652 Reduced 0.54%
669,327 $1.65 Million
Q3 2021

Nov 15, 2021

SELL
$5.1 - $9.39 $230,642 - $424,653
-45,224 Reduced 6.3%
672,979 $5.75 Million
Q2 2021

Aug 13, 2021

BUY
$3.95 - $6.88 $199,893 - $348,169
50,606 Added 7.58%
718,203 $4.6 Million
Q1 2021

May 12, 2021

BUY
$2.01 - $5.55 $537,001 - $1.48 Million
267,165 Added 66.72%
667,597 $2.96 Million
Q4 2020

Feb 11, 2021

SELL
$1.73 - $2.13 $29,193 - $35,943
-16,875 Reduced 4.04%
400,432 $849,000
Q3 2020

Nov 16, 2020

BUY
$1.76 - $2.17 $508,793 - $627,318
289,087 Added 225.46%
417,307 $743,000
Q2 2020

Aug 14, 2020

BUY
$1.75 - $2.65 $141,912 - $214,896
81,093 Added 172.07%
128,220 $271,000
Q1 2020

May 14, 2020

BUY
$1.15 - $3.29 $28,749 - $82,250
25,000 Added 112.98%
47,127 $93,000
Q3 2018

Nov 14, 2018

BUY
$1.11 - $1.64 $24,560 - $36,288
22,127 New
22,127 $29,000

Others Institutions Holding PAVM

# of Institutions
1
Shares Held
2.24M
Call Options Held
0
Put Options Held
0

About PAVmed Inc.


  • Ticker PAVM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 90,999,104
  • Market Cap $74.6M
  • Description
  • PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted ne...
More about PAVM
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.